Steeghs EMP, Gelderblom H, Ho VKY, Voorham QJM, Willems SM, Grünberg K, Ligtenberg MJL, PATH consortium. Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. Gastric Cancer. 2021;24(5):990–1002. https://doi.org/10.1007/s10120-021-01190-9.
CAS Article PubMed PubMed Central Google Scholar
Zeng C, Zhu L, Jia X, Pang Y, Li Z, Lu X, Xie F, Duan L, Wang Y. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Gastric Cancer. 2020;23(5):837–47. https://doi.org/10.1007/s10120-020-01069-1.
CAS Article PubMed Google Scholar
Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, et al. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene. 2021;40:1957–73.
CAS PubMed PubMed Central Article Google Scholar
Chen Y, Dong X, Wang Q, Liu Z, Dong X, Shi S, et al. Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia. Front Pharmacol. 2020;11:569843.
CAS PubMed PubMed Central Article Google Scholar
Boichuk S, Galembikova A, Mikheeva E, Bikinieva F, Aukhadieva A, Dunaev P, et al. Inhibition of FGF2-mediated signaling in GIST-promising approach for overcoming resistance to imatinib. Cancers (Basel). 2020;12:1674.
Proudman D, Miller A, Nellesen D, Gomes A, Mankoski R, Norregaard C, et al. Financial implications of avapritinib for treatment of unresectable gastrointestinal stromal tumors in patients with a PDGFRA Exon 18 variant or after 3 previous therapies in a hypothetical US health plan. JAMA Netw Open. 2020;3:e2025866.
PubMed PubMed Central Article Google Scholar
Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2.
CAS PubMed PubMed Central Article Google Scholar
Narjoz C, Favre A, McMullen J, Kiehl P, Montemurro M, Figg WD, et al. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. PLoS ONE. 2014;9:e95532.
PubMed PubMed Central Article CAS Google Scholar
Théou N, Gil S, Devocelle A, Julié C, Lavergne-Slove A, Beauchet A, et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res. 2005;11:7593–8.
PubMed Article CAS Google Scholar
Zhang Q, Li Z, Xu K, Qian Y, Chen M, Sun L, et al. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor. Scand J Gastroenterol. 2019;54:220–6.
CAS PubMed Article Google Scholar
Kumar V, Singh P, Gupta SK, Ali V, Verma M. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022. https://doi.org/10.1007/s11010-022-04376-6.
Article PubMed PubMed Central Google Scholar
Wang Q, Jiang ZP, Zeng J, Zhu Y, Cai HL, Xiang DX, et al. Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in Chinese patients with chronic myeloid leukemia. J Pharm Pharm Sci. 2020;2:1–9.
Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575:229–33.
CAS PubMed PubMed Central Article Google Scholar
Llopis B, Robidou P, Tissot N, Pinna B, Gougis P, Aubart FC, et al. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. J Pharm Biomed Anal. 2021;197:113968.
CAS PubMed Article Google Scholar
Rutkowski P, Ziętek M, Cybulska-Stopa B, Streb J, Głuszek S, Jankowski M, et al. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. Eur J Surg Oncol. 2021;47:1191–5.
Tartaggia S, Meneghello A, Bellotto O, Poetto AS, Zanchetta M, Posocco B, et al. An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma. Analyst. 2021;146:1714–24.
CAS PubMed Article Google Scholar
Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. https://doi.org/10.1016/j.ctrv.2020.101993.
CAS Article PubMed Google Scholar
Elseud YA, Shaaban A, Mohanty A, Albarrak J. Safety and tolerability of regorafenib: a real-life experience. J Gastrointest Cancer. 2021. https://doi.org/10.1007/s12029-020-00570-1.
Chang YR, Huang WK, Wang SY, Wu CE, Chen JS, Yeh CN. A nomogram predicting progression free survival in patients with gastrointestinal stromal tumor receiving sunitinib: incorporating pre-treatment and post-treatment parameters. Cancers (Basel). 2021;13(11):2587. https://doi.org/10.3390/cancers13112587.
Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y, Jia X, Lee JC, Wang Y. Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res. 2021;81(9):2481–94. https://doi.org/10.1158/0008-5472.CAN-20-3580.
CAS Article PubMed Google Scholar
Grunewald S, Klug LR, Mühlenberg T, Lategahn J, Falkenhorst J, Town A, Ehrt C, Wardelmann E, Hartmann W, Schildhaus HU, Treckmann J, Fletcher JA, Jung S, Czodrowski P, Miller S, Schmidt-Kittler O, Rauh D, Heinrich MC, Bauer S. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 2021;11(1):108–25. https://doi.org/10.1158/2159-8290.CD-20-0487.
CAS Article PubMed Google Scholar
Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. https://doi.org/10.1016/S1470-2045(20)30168-6.
CAS Article PubMed PubMed Central Google Scholar
Carriot N, Paix B, Greff S, Viguier B, Briand JF, Culioli G. Integration of LC/MS-based molecular networking and classical phytochemical approach allows in-depth annotation of the metabolome of non-model organisms—the case study of the brown seaweed Taonia atomaria. Talanta. 2021;225:121925.
CAS PubMed Article Google Scholar
Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;6(58):663–87. https://doi.org/10.1146/annurev-pharmtox-010617-052713.
Brosseau N, Ramotar D. The human organic cation transporter OCT1 and its role as a target for drug responses. Drug Metab Rev. 2019;51:389–407.
CAS PubMed Article Google Scholar
Morse BL, Kolur A, Hudson LR, Hogan AT, Chen LH, Brackman RM, et al. Pharmacokinetics of organic cation transporter 1 (OCT1) substrates in Oct1/2 knockout mice and species difference in hepatic OCT1-mediated uptake. Drug Metab Dispos. 2020;48:93–105.
CAS PubMed Article Google Scholar
Chang HH, Hsueh YS, Cheng YW, Ou HT, Wu MH. Association between polymorphisms of OCT1 and metabolic response to metformin in women with polycystic ovary syndrome. Int J Mol Sci. 2019;20:1720.
CAS PubMed Central Article Google Scholar
Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. 2017;102(5):843–53. https://doi.org/10.3324/haematol.2016.153270.
CAS Article PubMed PubMed Central Google Scholar
Xinwei D, Gang J, Songtao M, Yan C. Simultaneous determine of imatinib myslate and its metabolites in human plasma by two-dimensional liquid chromatography: a methodological study. J Cancer Control Treat. 2021;34(10):919–26.
Wang Q, Jiang ZP, Zeng J, Zhu Y, Cai HL, Xiang DX, et al. Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in chinese patients with chronic myeloid leukemia. J Pharm Pharm Sci. 2020;23:1–9.
Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 2017;77(18):5107–17. https://doi.org/10.1158/0008-5472.CAN-17-0917.
CAS Article PubMed Google Scholar
Zhou Y, Chen J, Weng X, Lin G, Huang Z, Shui H. Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate. Oncol Lett. 2018;15(5):7589–94. https://doi.org/10.3892/ol.2018.8283.
CAS Article PubMed PubMed Central Google Scholar
Chen K, Ren Q, Han XR, Zhang XN, Wei B, Bai XZ. Imatinib mesylate induces mitochondria-dependent apoptosis and inhibits invasion of human pigmented villonodular synovitis fibroblast-like synovial cells. Oncol Rep. 2016;35(1):197–204. https://doi.org/10.3892/or.2015.4350.
CAS Article PubMed Google Scholar
Su B, Huang T, Jin Y, Yin H, Qiu H, Yuan X. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways. Gastric Cancer. 2021;24(2):352–67. https://doi.org/10.1007/s10120-020-01126-9.
CAS Article PubMed Google Scholar
Vetter TR. Fundamentals of research data and variables: the devil is in the details. Anesth Analg. 2017;125:1375–80.
留言 (0)